Screener
Intellia Therapeutics NTLA Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 120,419 | 124,241 | 235,999 | 261,675 |
| Operating loss | (112,760) | (109,996) | (213,292) | (230,803) |
| Other income, net: | ||||
| Interest income | 5,797 | 7,402 | 11,002 | 16,005 |
| Change in fair value of investments, net | 329 | 1,339 | (575) | (786) |
| Total other income, net | 6,126 | 8,741 | 10,427 | 15,219 |
| Net loss | $(106,634) | $(101,255) | $(202,865) | $(215,584) |
| Net loss per share, basic and diluted | $(0.80) | $(0.98) | $(1.61) | $(2.08) |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's interest income?
- Intellia Therapeutics (NTLA) reported interest income of $5.8M in Q2 2026.
- How has Intellia Therapeutics's interest income changed year-over-year?
- Intellia Therapeutics's interest income decreased by 21.7% year-over-year, from $7.4M to $5.8M.
- What is the long-term trend for Intellia Therapeutics's interest income?
- Over 4 years (2021 to 2025), Intellia Therapeutics's interest income has grown at a 118.4% compound annual growth rate (CAGR), from $1.28M to $29.2M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Intellia Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude